Phibro Animal Health to report Q4 FY26 results on August 26
Phibro Animal Health Corporation (NASDAQ: PAHC) is scheduled to announce its fourth quarter and fiscal year 2026 financial results after market close on Wednesday, August 26, 2026. Management will host a conference call and webcast on Thursday, August 27, 2026, at 9:00 am ET to discuss these results. Investors can access the live event via the company's investor relations website or by phone using Conference ID 3927884.
Phibro Animal Health CFO David Glenn Awarded 3,334 RSUs on August 6, 2026
David Glenn, CFO of Phibro Animal Health Corp (NASDAQ: PAHC), was awarded 3,334 restricted stock units (RSUs) of Class A Common Stock on August 6, 2026. The filing for this acquisition was made on August 10, 2026, with the RSUs valued at $0.
Phibro Animal Health (PAHC) awards 3,522 RSUs to Chief Operating Officer
Phibro Animal Health Corp (PAHC) has granted 3,522 restricted stock units (RSUs) to its Chief Operating Officer, Larry Lee Miller. These RSUs, representing Class A Common Stock, will vest in three equal installments over three years, contingent on his continued employment. Following this grant, Miller directly holds 38,071 shares of Class A Common Stock, including the newly awarded RSUs.
Phibro Animal Health (PAHC) grants 12,103 RSUs to Executive Chairman Bendheim
Phibro Animal Health Corp. (PAHC) Executive Chairman and 10% owner Jack Bendheim was granted 12,103 restricted stock units (RSUs). These RSUs, each representing one share of Class A Common Stock, will vest in equal installments over the first three anniversaries of August 1, 2026, contingent on his continued employment. Following this grant, Bendheim directly holds 26,640 Class A shares and has shared voting and investment power over an additional 56,152 Class A shares held by BFI Co., LLC.
Phibro Animal Health (NASDAQ: PAHC) awards 1,503 RSUs to VP Finance
Phibro Animal Health Corp (NASDAQ: PAHC) has awarded its VP Finance and Treasurer, Patrick Rodriguez, 1,503 restricted stock units (RSUs) representing Class A Common Stock. These RSUs will vest in substantially equal installments over the first three anniversaries of August 1, 2026, contingent on his continued employment. Following this award, Rodriguez directly holds 1,503 shares of Class A Common Stock, with the transaction valued at $0.00 per share, consistent with a compensation award.
Phibro Animal Health (PAHC) grants 11,699 RSUs to President and CEO
Phibro Animal Health (PAHC) reported that its President and CEO, Daniel M. Bendheim, was granted 11,699 restricted stock units (RSUs). These RSUs represent a contingent right to receive one share of Class A Common Stock each, vesting in three equal annual installments beginning August 1, 2026, contingent on his continued employment. Following this grant, Bendheim directly holds 15,177 shares of Class A Common Stock, including the newly awarded RSUs.
Phibro Animal Health (PAHC) awards 1,547 RSUs to SVP of Human Resources
Phibro Animal Health (PAHC) awarded 1,547 restricted stock units (RSUs) to Lisa Ann Escudero, SVP of Human Resources, on August 6, 2026. These RSUs will vest in three equal installments on the first three anniversaries of August 1, 2026, contingent on her continued employment. Following this grant, Escudero directly holds 3,434 shares or share-equivalent RSUs of Class A Common Stock.
Phibro Animal Health (NASDAQ: PAHC) awards 2,478 RSUs to senior legal officer
Phibro Animal Health Corp (NASDAQ: PAHC) has awarded 2,478 Restricted Stock Units (RSUs) to Judith Weinstein, its Senior Vice President and General Counsel. This grant increases her direct holdings to 5,453 shares. The RSUs will vest in substantially equal installments over three years, beginning August 1, 2026, contingent upon her continued employment.
Phibro Animal Health (PAHC) grants 2,716 RSUs to director Jonathan Bendheim
Phibro Animal Health (PAHC) director Jonathan Bendheim was granted 2,716 restricted stock units (RSUs) on August 6, 2026. These RSUs represent a contingent right to receive one share of Class A Common Stock each, and they will vest in substantially equal installments on the first three anniversaries of August 1, 2026, provided Bendheim remains employed. Following this transaction, Bendheim directly holds 5,984 shares of Class A Common Stock.
Phibro Animal Health (NASDAQ: PAHC) CFO receives 3,334-share restricted stock grant
Phibro Animal Health (NASDAQ: PAHC) CFO David Glenn was granted 3,334 restricted stock units (RSUs). These RSUs, which represent Class A Common Stock, were awarded at a price of $0.00 per share and will vest in three equal annual installments starting August 1, 2026, contingent on his continued employment. Following this grant, Glenn's direct holdings in Class A Common Stock total 54,811 shares.
Phibro Animal Health (PAHC) CFO sells 840 shares to cover taxes
Phibro Animal Health's CFO, David Glenn, disposed of 840 shares of Class A Common Stock on August 4, 2026, at an average price of $36.599 per share. This transaction was a broker-assisted cashless exercise performed to satisfy tax withholding obligations related to the vesting of restricted stock units. Following this disposition, Glenn directly owns 51,477 shares of PAHC.
Phibro Animal Health (NASDAQ: PAHC) COO sells 635 shares for tax withholding
Phibro Animal Health's Chief Operating Officer, Larry Lee Miller, sold 635 shares of Class A Common Stock on August 4, 2026, at a price of $36.599 per share. This transaction was a broker-assisted cashless exercise to cover tax withholding obligations associated with the vesting of restricted stock units. Following the sale, Miller directly holds 34,549 shares of the company.
Phibro Animal Health (NASDAQ: PAHC) GC sells 472 shares for taxes
Phibro Animal Health's General Counsel, Judith Weinstein, sold 472 shares of Class A Common Stock on August 4, 2026, at $36.599 per share. This transaction was a broker-assisted cashless exercise to cover tax withholding obligations upon the vesting of restricted stock units. Following this sale, Weinstein directly holds 2,975 shares of Class A Common Stock.
CEO of Phibro Animal Health (NASDAQ: PAHC) sells 486 shares for taxes
Daniel M Bendheim, President and CEO of Phibro Animal Health (PAHC), reported selling 486 shares of Class A Common Stock for $36.599 per share on August 4, 2026. This transaction was a broker-assisted cashless sale to cover tax withholding obligations associated with the vesting of restricted stock units. After the sale, Bendheim directly holds 3,478 shares.
Phibro Animal Health (PAHC) chair disposes 2,303 shares to cover tax withholding
Jack Bendheim, Executive Chairman and 10% owner of Phibro Animal Health (PAHC), disposed of 2,303 shares of Class A Common Stock on August 4, 2026. This transaction was conducted through a broker-assisted cashless exercise program to cover tax withholding obligations upon the vesting and settlement of restricted stock units. Following this, Bendheim directly holds 14,537 Class A shares and indirectly holds 56,152 shares through BFI Co., LLC.
FMR LLC discloses 15% ownership of Phibro Animal Health (PAHC) Class A shares
FMR LLC and Abigail P. Johnson have reported a 15.0% beneficial ownership stake in Phibro Animal Health Corp's Class A common stock, totaling 3,160,280.92 shares as of June 30, 2026. FMR LLC holds sole voting power over 3,159,853 shares and sole dispositive power over all reported shares, while Abigail P. Johnson has sole dispositive power over the same amount but no voting power. This disclosure, filed as an amended Schedule 13G/A, indicates that other individuals may have dividend or sale proceeds rights but none exceed 5% ownership.
Phibro Animal Health (PAHC) HR chief sells 265 shares to cover tax withholding
Lisa Ann Escudero, SVP of Human Resources at Phibro Animal Health (PAHC), sold 265 shares of Class A Common Stock on August 4, 2026, to cover tax withholding obligations associated with the vesting of restricted stock units. The transaction was a broker-assisted cashless sale at $36.599 per share. After this sale, Escudero directly holds 1,887 shares of PAHC.
PHIBRO ANIMAL HEALTH CORP SEC Filing (Aug 4, 2026)
This article details a Form 144 SEC filing by Phibro Animal Health Corp (PAHC) on August 4, 2026. The filing indicates a proposed sale of 486 shares of Class A common stock by an individual, acquired through restricted stock vesting. The aggregate market value of the shares to be sold is $17,787.31, with the sale expected on August 4, 2026, on NASDAQ.
Millennium group (NASDAQ: PAHC) discloses 1.06M-share Phibro Animal Health position
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported beneficial ownership of 1,064,608 shares of Phibro Animal Health Corporation (PAHC) Class A common stock, which represents 5.1% of the class. They indicate shared voting and dispositive power over these shares, with no sole voting or dispositive power. The securities are held by entities managed by Millennium Management LLC and its affiliates, with Mr. Englander as a key figure in control, emphasizing that this report does not admit beneficial ownership beyond the filing requirements.
Phibro Animal Health declares $0.12 quarterly dividend payable Sept. 23
Phibro Animal Health (PAHC) has declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock. The dividend is payable on September 23, 2026, to shareholders of record as of September 2, 2026. This announcement was filed as an Exhibit 99.1 to the company's Form 8-K on July 28, 2026.
Phibro shareholders set to receive $0.12 dividend Sept. 23
Phibro Animal Health Corporation announced a quarterly cash dividend of $0.12 per share for its Class A and Class B common stock. The dividend is payable on September 23, 2026, to stockholders of record as of September 2, 2026. Phibro Animal Health is a global animal health and nutrition company.
Las ETF que invierten en acciones de Phibro Animal Health Corporation Class A
This article lists various ETFs that invest in Phibro Animal Health Corporation Class A stock, primarily focusing on small-cap and healthcare-related funds. It provides detailed financial data for each ETF, including market value, weight, issuer, management style, expense ratio, and total returns. The information aims to assist investors interested in the stock by showcasing diversified investment opportunities with potentially lower risk.
Is Phibro Animal Health (PAHC) Undervalued After Its Russell Index Removal?
Phibro Animal Health (PAHC) has been removed from several Russell indices, impacting potential ownership and liquidity. Despite a recent stock performance dip, the company is considered 29.6% undervalued by analysts, with a fair value target of $45.60 compared to its current $32.10. However, its core business faces challenges from consumer preferences and regulatory scrutiny regarding antibiotic use, which could affect future margins and earnings.
Phibro (NASDAQ: PAHC) CEO receives 300,000 performance units award
Phibro Animal Health Corporation's President and CEO, Daniel M. Bendheim, has been granted 300,000 Performance Stock Units (PSUs). These PSUs represent a contingent right to receive Class A Common Stock, with vesting scheduled for June 30, 2031, subject to the achievement of specified stock price performance and Bendheim’s continued employment. This insider transaction was reported in a Form 4 filing, indicating a neutral impact and sentiment.
Enterprise value to revenue forward of Phibro Animal Health Corporation Class A – MUN:PB8
This article provides financial metrics for Phibro Animal Health Corporation Class A (MUN:PB8) on the Munich Stock Exchange, specifically focusing on its enterprise value to revenue forward. It appears to be a financial data point from TradingView, offering a snapshot of the company's valuation.
Price to earnings forward of Phibro Animal Health Corporation Class A – MUN:PB8
This article provides financial information for Phibro Animal Health Corporation Class A (MUN:PB8) on the Munich Stock Exchange, specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of publication with no trades. The content is primarily a data page from TradingView.
Price to sales forward of Phibro Animal Health Corporation Class A – MUN:PB8
This article displays the "Price to sales forward" value for Phibro Animal Health Corporation Class A under its Munich Stock Exchange ticker PB8. The financial data provided is limited, indicating that no specific trades or values are currently available. It appears to be a stub or a pre-filled page from TradingView.
New Phibro (NASDAQ: PAHC) CEO granted 300,000 performance-based RSUs
Phibro Animal Health Corporation announced the appointment of Daniel (Dani) Bendheim as CEO and President, effective July 1, 2026. His compensation package includes an $850,000 annual base salary, a target 50% annual cash bonus, annual time-vesting RSUs, and an initial grant of 300,000 performance-based RSUs. These performance RSUs are set to vest by June 30, 2031, contingent on the company's 90-day average share price reaching between $70 and $100.
Price to book forward of Phibro Animal Health Corporation Class A – GETTEX:PB8
The article provides a title for the "Price to book forward" metric for Phibro Animal Health Corporation Class A shares traded on GETTEX under the symbol PB8. It indicates that the market is currently closed with no trades. The content seems to be a template or header from a financial data platform like TradingView.
Phibro Animal Health Corporation Class A Actuals & Estimates (NASDAQ:PAHC)
This article provides an overview of Phibro Animal Health Corporation (NASDAQ:PAHC) stock, detailing its current price, market capitalization, and historical performance. It also includes analyst forecasts for future prices, upcoming earnings dates, and financial data such as revenue, net income, and dividend information, while clarifying that the content is not investment advice.
PHIBRO ANIMAL HEALTH CORP SEC Filing
Phibro Animal Health Corporation filed a Form 144 notice, disclosing proposed sales of 281,600 shares of Class A Common Stock. The filing details multiple smaller transactions by BFI Co. LLC, handled by Goldman Sachs & Co. LLC, which occurred between March and May 2026. These filings are procedural disclosures for resale activity under Rule 144.
Phibro Animal Health Up 10% After Insider Move
Phibro Animal Health Corp shares rose over 10% following a director's purchase of Class A shares on the open market after a recent decline, despite ongoing investor concerns about Brazil's regulatory environment and the company's guidance. The company announced a quarterly cash dividend of 12 cents per share, and its latest quarterly net sales and adjusted EBITDA saw significant increases. However, recent analyst ratings have been cautious, with a consensus put at "Hold."
Phibro Animal Health director E. Thomas Corcoran buys $317,700 in stock
Phibro Animal Health Corp. director E. Thomas Corcoran purchased 10,000 shares of the company's Class A Common Stock for $317,700 on May 29, 2026, at a weighted average price of $31.77 per share. This transaction increased his direct holdings to 41,459 shares. The purchase occurred shortly after the company announced strong Q3 fiscal year 2026 results, exceeding analyst expectations for both EPS and revenue, despite a subsequent dip in the stock price.
Phibro Animal Health director E. Thomas Corcoran buys $317,700 in stock By Investing.com
E. Thomas Corcoran, a director at Phibro Animal Health Corp. (NASDAQ:PAHC), recently purchased 10,000 shares of the company's Class A Common Stock for a total of $317,700. This transaction occurred on May 29, 2026, at an average price of $31.77 per share. Following this purchase, Corcoran now directly holds 41,459 shares, and the acquisition comes as the stock trades at $28.52, down 15% over the past week, following a negative market reaction to strong Q3 fiscal year 2026 financial results that exceeded analyst forecasts.
Phibro Animal Health (PAHC) director buys 10,000 shares in market
E. Thomas Corcoran, a director at Phibro Animal Health (PAHC), purchased 10,000 shares of Class A Common Stock in an open-market transaction. The shares were bought at a weighted average price of $31.77 per share. Following this acquisition, Corcoran directly holds 41,459 shares, which includes shares obtained through a dividend reinvestment plan.
Phibro Animal Health (NasdaqGM:PAHC) Stock Forecast & Analyst Predictions
Phibro Animal Health (PAHC) is forecast to grow earnings by 15.1% and revenue by 3% annually, with EPS expected to increase by 14.9% per annum. Recent updates detail Q3 2026 earnings beats, raised outlooks, and the launch of a new sustainable solutions platform, Verratain. Analyst sentiment is cautious around valuation but acknowledges operational progress, although dividend sustainability and debt coverage remain minor risks.
Phibro Animal Health (PAHC) major holder adopts 10b5-1 sale plan
BFI Co., LLC and Jack C. Bendheim, major holders in Phibro Animal Health (PAHC), have filed an amended Schedule 13D disclosing a new Rule 10b5-1 sales plan. This plan authorizes Goldman Sachs to sell up to 750,000 shares of Class A Common Stock by March 17, 2027, with the first trading date on September 16, 2026. BFI currently beneficially owns 48.2% of PAHC's Class A Common Stock on an as-converted basis, and would still retain a substantial stake even if all shares under the plan are sold.
Phibro Animal Health Corporation to Participate in Stifel Jaws & Paws Conference
Phibro Animal Health Corporation (Nasdaq: PAHC) announced its participation in the Stifel Jaws & Paws Conference. Key executives, including Daniel Bendheim, Larry Miller, and Glenn David, will address financial analysts and investors on May 27, 2026, at 9:45 AM ET in New York. A live audio presentation and replay will be available on the company's Investor Relations website.
Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
Phibro Animal Health Corporation announced strong financial results for its third quarter ended March 31, 2026, with net sales increasing by 10% to $383.5 million and adjusted EBITDA rising by 11% to $60.8 million, largely driven by its Animal Health business. The company also updated its fiscal year 2026 guidance, increasing the lower end of several ranges due to improved performance and visibility, and expanded its revolving credit facility by $125 million. Additionally, Phibro launched its VERRATAIN™ Verified Sustainability Solutions platform.
Barclays PLC holds 263,695 shares in Phibro (NASDAQ: PAHC)
Barclays PLC has filed an amended Schedule 13G/A, indicating beneficial ownership of 263,695 shares of Phibro Animal Health Corp-A common stock, which represents 1.27% of the class. The filing specifies that Barclays holds sole voting and dispositive power over these shares. This amendment, signed by a Barclays director on May 14, 2026, provides transparency on institutional holdings without implying control over the issuer.
Phibro Animal Health (PAHC) Margin Reset To 6.3% Tests Bullish Expansion Narrative
Phibro Animal Health (PAHC) recently reported Q3 2026 results with revenue of US$383.5 million and EPS of US$0.59. The company's trailing 12-month net profit margin is 6.3%, up from 2.7% previously, but quarterly net income has been stable between US$24.0 million and US$27.5 million. While earnings growth significantly outpaces revenue growth, the stock's P/E ratio is higher than industry averages, creating a tension for investors despite a discount to its DCF fair value.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation (Nasdaq: PAHC) announced a quarterly cash dividend of $0.12 per share for its Class A and Class B common stock. The dividend is payable on June 24, 2026, to shareholders of record as of June 3, 2026. Phibro Animal Health Corporation is a global animal health and nutrition company providing solutions for farm and companion animals.
Phibro Animal Health Corporation to Participate in Bank of America Securities Health Care Conference
Phibro Animal Health Corporation announced its participation in the Bank of America Securities Health Care Conference. Key executives, including Daniel Bendheim, Larry Miller, and Glenn David, will address financial analysts and investors on May 13, 2026, at 1:40 PM ET. A live audio presentation and replay will be available on the company's Investor Relations Website.
Phibro Animal Health CEO Jack Bendheim sells $1.02m in PAHC shares
Phibro Animal Health CEO Jack Bendheim, along with BFI Co., LLC, sold Class A Common Stock worth approximately $1.02 million between May 5 and May 7, 2026, under a Rule 10b5-1 trading plan. These sales involved 18,608 shares at prices ranging from $47.5908 to $58.1257, occurring despite the company's stock currently trading lower than the transaction prices but after a strong annual return. The insider sales follow Phibro's positive third-quarter fiscal 2026 results which surpassed Wall Street expectations for EPS and revenue.
CEO-linked BFI Co. (PAHC) sells 18,608 Phibro shares under plan
BFI Co., LLC, an entity linked to Phibro Animal Health's CEO Jack Bendheim, sold 18,608 shares of Class A Common Stock between May 5-7, 2026, under a pre-arranged Rule 10b5-1 trading plan. The shares were sold in open-market transactions at weighted average prices ranging from approximately $47 to $58 per share. Following these sales, BFI Co., LLC indirectly holds 56,152 shares, while Jack Bendheim directly holds 16,840 shares, though he disclaims beneficial ownership of BFI's holdings beyond his pecuniary interest.
Phibro Animal Health CEO Jack Bendheim sells $1.02m in PAHC shares
Phibro Animal Health CEO Jack Bendheim, along with BFI Co., LLC, sold approximately $1.02 million worth of Class A Common Stock in PAHC between May 5 and May 7, 2026, under a Rule 10b5-1 trading plan. The shares were sold at prices ranging from $47.5908 to $58.1257. These transactions occurred amidst stock volatility, despite the company's strong recent fiscal 2026 Q3 results which surpassed analyst expectations.
Phibro Animal Health Corporation Launches Companywide Sustainable Solutions Platform; Introduces VERRATAIN™ Verified Sustainability Solutions Through Strategic VAXA Technologies Partnership
Phibro Animal Health Corporation has launched its Sustainable Solutions Platform (SSP), a companywide initiative to help animal protein, dairy, and petfood producers reduce greenhouse gas emissions. As part of this, Phibro introduced Verratain™ Verified Sustainability Solutions, starting with a partnership with VAXA Technologies to offer low-carbon microalgae feed ingredients like Verratain™ Spirulina and Verratain™ Omega Oil, which target Scope 3 emissions in animal feed supply chains. Peter Bunce has been appointed Head of Sustainable Solutions to lead this platform, aiming to provide scalable and practical solutions for sustainability goals.
Phibro Animal Health declares $0.12 quarterly dividend payable June 24
Phibro Animal Health (PAHC) has declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock. This dividend is payable on June 24, 2026, to shareholders of record as of June 3, 2026. The declaration was announced on May 5, 2026, and details were filed as Exhibit 99.1 to the company's Form 8-K.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation (Nasdaq: PAHC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock. This dividend is payable on June 24, 2026, to stockholders of record as of June 3, 2026. Phibro Animal Health Corporation is a global diversified animal health and nutrition company.
[8-K] PHIBRO ANIMAL HEALTH CORP Reports Material Event
Phibro Animal Health Corporation announced an 8-K material event, declaring a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock. The dividend will be paid on June 24, 2026, to stockholders recorded by June 3, 2026. This filing, deemed a moderate impact with neutral sentiment, voluntarily discloses an important event for shareholders.
